Coadministration of Cariprazine with a Moderate CYP3A4 Inhibitor in Patients with Schizophrenia: Implications for Dose Adjustment and Safety Monitoring - Szabó, Máté; Hujber, Zoltán; Harsányi, Judit; Szatmári, Balázs; Dombi, Zsófia B.; Magyar, Gabriella; Hegedűs, Zsuzsanna; Ratskó, Piroska; Pásztor Mészáros, Gabriella; Barabássy, Ágota (Clinical pharmacokinetics, 2024)
Keywords: Adult; Antipsychotic Agents - administration & dosage; Antipsychotic Agents - adverse effects; Antipsychotic Agents - pharmacokinetics; Antipsychotic Agents - therapeutic use; Antipsychotics; Area Under Curve; Cytochrome; Cytochrome P-450 CYP2D6 - genetics; Cytochrome P-450 CYP2D6 - metabolism; Cytochrome P-450 CYP3A - metabolism; Cytochrome P-450 CYP3A Inhibitors - administration & dosage; Cytochrome P-450 CYP3A Inhibitors - pharmacokinetics; Cytochrome P-450 CYP3A Inhibitors - pharmacology; Drug dosages; Drug Interactions; Enzymes; Erythromycin - administration & dosage; Erythromycin - pharmacokinetics; Erythromycin - pharmacology; Humans; Internal Medicine; Male; Medicine; Medicine & Public Health; Metabolism; Metabolites; Middle Aged; Original; Original Research Article; Pharmacokinetics; Pharmacology/Toxicology; Pharmacotherapy; Piperazines - administration & dosage; Piperazines - pharmacokinetics; Piperazines - therapeutic use; Psychotropic drugs; Registration; Schizophrenia; Schizophrenia - drug therapy; Young Adult